We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

89 hedge funds and large institutions have $1.09B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2013 Q2 according to their latest regulatory filings, with 89 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $597K

Holders
89
Holders Change
+89
Holders Change %
–
% of All Funds
2.9%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
89
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
$597K
Net Calls
-$597K
Net Calls Change
-$597K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$387M +$420M +9,223,182 New
Capital Research Global Investors
2
Capital Research Global Investors
California
$140M +$151M +3,321,802 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$118M +$128M +2,806,087 New
CWAM
4
Columbia Wanger Asset Management
Illinois
$104M +$113M +2,485,288 New
JHIU
5
Janus Henderson Investors US
Colorado
$51.1M +$55.5M +1,216,922 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$27.6M +$29.9M +656,240 New
BFA
7
BlackRock Fund Advisors
California
$26.9M +$29.2M +641,098 New
State Street
8
State Street
Massachusetts
$18.6M +$20.2M +443,595 New
AllianceBernstein
9
AllianceBernstein
Tennessee
$18.6M +$20.1M +442,058 New
BIT
10
BlackRock Institutional Trust
California
$16.6M +$18M +394,585 New
FAM
11
Fred Alger Management
New York
$15.9M +$17.3M +379,270 New
BA
12
BlackRock Advisors
Delaware
$13.3M +$14.5M +317,363 New
Capital World Investors
13
Capital World Investors
California
$9.45M +$10.3M +225,000 New
TI
14
Turner Investments
Pennsylvania
$8.81M +$9.56M +209,744 New
Wells Fargo
15
Wells Fargo
California
$8.8M +$9.56M +209,742 New
Northern Trust
16
Northern Trust
Illinois
$7.99M +$8.68M +190,398 New
Lord, Abbett & Co
17
Lord, Abbett & Co
New Jersey
$7.39M +$8.02M +175,978 New
Wellington Management Group
18
Wellington Management Group
Massachusetts
$6.56M +$7.12M +156,240 New
PAMU
19
Pictet Asset Management (UK)
United Kingdom
$6.51M +$7.06M +155,000 New
DCM
20
Driehaus Capital Management
Illinois
$6.23M +$6.76M +148,411 New
EA
21
Emerald Advisers
Pennsylvania
$6.22M +$6.76M +148,232 New
Goldman Sachs
22
Goldman Sachs
New York
$5.2M +$5.64M +123,865 New
CII
23
CR Intrinsic Investors
Connecticut
$4.96M +$5.38M +118,161 New
Ameriprise
24
Ameriprise
Minnesota
$4.82M +$5.22M +114,627 New
Millennium Management
25
Millennium Management
New York
$4.55M +$4.94M +108,443 New
1
2 3 4

GEVA Hedge Fund Activity: Q2 2013 in Review

89 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q2 2013, worth a combined $1.09B.

Buyers outnumbered sellers: 89 funds opened new GEVA positions and 0 closed out — a net gain of 89 holders — while 0 added to existing stakes and 0 trimmed.

  • 89 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $1.09B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q2 2013.
  • 89 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q2 2013 and 0 closed out, a net change of +89 holders.

Based on aggregated 13F filings for Q2 2013.